Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of docosahexaenoic acid on retinopathy of prematurity in premature newborns
IRCT20211226053528N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of docosahexaenoic acid in retinopathy of prematurity (ROP), sponsored by Iran University of Medical Sciences. Started Mar 2021; status: completed.
02
Drugs
docosahexaenoic acid
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on IRCT20211226053528N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211226053528N1.